Figure 1.

Inhibition of platelet activation or degranulation, but not GPIIb/IIIa blockade results in reduced infarct sizes in experimental stroke. Blockade or genetic deficiency of GPIbα, GPVI, P2Y₁, P2Y₁₂, PAR1, or PAR4 reduces infarct sizes following cerebral ischemia/reperfusion injury. Likewise, lack of either dense (δ) or α-granule secretion improves the outcome following experimental stroke. In contrast, combined loss of dense and α-granule secretion or GPIIb/IIIa-blockade is accompanied by intracranial hemorrhage. See text for details.